Appili Therapeutics Inc Class A (APLIF) AI Stock Analysis

Appili Therapeutics Inc Class A

(Other OTC:APLIF)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Reported Revenue GrowthThe reported revenue growth rate indicates that the company has expanded its current revenue base materially. If supported by continued development progress and customer or partner activity, this growth can improve operating leverage and strengthen the commercial foundation over the next several quarters.

Negative Factors

Severely Stressed Balance SheetNegative equity and debt that materially exceeds the asset base indicate very limited financial flexibility. This structure can constrain investment in clinical programs, increase refinancing dependence, and raise the likelihood that future funding could dilute existing shareholders.

Appili Therapeutics Inc Class A (APLIF) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $926.56K
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -0.1
Beta (1Y): 0.75
Revenue Growth: 252.01%
EPS Growth: -91.97%
Country: US
Employees: 7
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Pharmaceuticals

Appili Therapeutics Inc Class A Business Overview & Revenue Model

Company Description

Appili Therapeutics, Inc. is a biopharmaceutical company, which engages in acquisition and development of novel treatments targeting unmet needs in infectious disease. It focuses on building and advancing a diverse portfolio of anti-infective program...

Appili Therapeutics Inc Class A Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

APLIF against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TSE:MIR	47Neutral	CAD 37.19M	-11.36	12.68%	―	45.72%	35.82%
TSE:KNE	37Underperform	CAD 6.15M	-2.05	273.53%	―	―	―
TSE:VXL	37Underperform	CAD 398.40K	1.00	34.52%	―	―	―
TSE:BIOV	29Underperform	CAD 2.04M	-0.91	69.89%	―	―	―

* Healthcare Sector Average

Performance Comparison

APLIF and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
APLIF	Appili Therapeutics Inc Class A	0.01	-0.01	-50.00%
TSE:KNE	Kane Biotech	0.03	0.00	0.00%
TSE:MIR	Medmira Inc	0.05	-0.02	-29.33%
TSE:VXL	Vaxil Bio	0.10	-0.07	-41.18%
TSE:BIOV	Biovaxys Technology Corp	0.07	-0.19	-73.08%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Appili Therapeutics Inc Class A AI Stock Analysis